Bio-Techne makes third acquisition this year

26 June 2018

USA-based purified protein maker Bio-Techne (Nasdaq: TECH) has reached agreement to acquire Waltham, MA-based Exosome Diagnostics for $250 million in cash plus contingent consideration of up to $325 million due upon the achievement of certain future milestones.

The transaction is expected to close in July or early August 2018, and will be financed through a combination of cash on hand and a revolving line of credit facility that Bio-Techne expects to obtain prior to the closing of the acquisition.

This is the third M&A deal this year for Bio-Techne, which is January announced the acquisition of all of the stock of Atlanta Biologicals and its affiliated company, Scientific Ventures, and earlier this month a deal to buy all of the stock of Atlanta Biologicals and its affiliated company, Scientific Ventures.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK